Testing effectiveness (Phase 2)Ended earlyNCT02323230
What this trial is testing
DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
Who this might be right for
Diffuse Large B-Cell Lymphoma
ImmunoVaccine Technologies, Inc. (IMV Inc.) 4